Safety considerations and potential interactions of vitamins: Should vitamins be considered drugs?

Annals of Pharmacotherapy

Volumn 44, Issue 2, 2010, Pages 311-324

  Rogovik, Alexander L ^a,b   Vohra, Sunita ^c,d   Goldman, Ran D ^e,f,g,h  

^a Pediatric Research in Emergency Therapeutics (PRETx) Program   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c STOLLERY CHILDREN S HOSPITAL   (Canada)

^d UNIVERSITY OF ALBERTA   (Canada)

^e Pediatric Research in Emergency Therapeutics (PRETx) Program   (Canada)

^f BC CHILDREN S HOSPITAL   (Canada)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Complementary and alternative medicine; Dietary supplements; Drugs; Vitamins

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; BETA CAROTENE; BIOTIN; CALCIUM CARBONATE; CORTICOSTEROID; CYANOCOBALAMIN; FATTY ACID; FOLIC ACID; GAMMA TOCOPHEROL; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; IBUPROFEN; NICOTINIC ACID; NON PRESCRIPTION DRUG; PANTOTHENIC ACID; PARACETAMOL; PLACEBO; PROSTATE SPECIFIC ANTIGEN; PYRIDOXINE; RETINOL; RETINOL PALMITATE; RIBOFLAVIN; SELENIUM; THIAMINE; UNINDEXED DRUG; VITAMIN; VITAMIN D; VITAMIN K GROUP;

ABDOMINAL CRAMP; ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALLERGIC REACTION; ANAPHYLAXIS; ANEMIA; ANOREXIA; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATAXIA; BLEEDING; BLOATING; BLOOD PRESSURE; BLOOD VESSEL CALCIFICATION; BLURRED VISION; BONE PAIN; BRAIN DISEASE; BREAST AUGMENTATION; BREAST CANCER; BRONCHOSPASM; CALCIFIC CONJUNCTIVITIS; CANCER INCIDENCE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM DISEASE; CEREBROSPINAL FLUID PRESSURE; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; COLLAPSE; COLORECTAL ADENOMA; CONFUSION; CONJUNCTIVITIS; CONTACT DERMATITIS; CORONARY ARTERY BYPASS GRAFT; CRANIOFACIAL MALFORMATION; CREATINURIA; CYANOCOBALAMIN DEFICIENCY; CYANOSIS; CYSTIC MACULOPATHY; DEATH; DERMATITIS; DIARRHEA; DIET SUPPLEMENTATION; DIETARY INTAKE; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG CONTROL; DRUG HYPERSENSITIVITY; DRUG INDUSTRY; DRUG INFORMATION; DRUG LABELING; DRUG MANUFACTURE; DRUG MARKETING; DRUG QUALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; ECZEMA; EMOTIONAL DISORDER; EOSINOPHILIC PLEUROPERICARDIAL EFFUSION; EPIPHYSIS CLOSURE; ERYTHEMA; ESOPHAGITIS; FATIGUE; FLATULENCE; FLUSHING; FOLLOW UP; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; GLUCOSE TOLERANCE; GLUCOSURIA; GONAD DYSFUNCTION; GOUT; GROWTH DISORDER; HEADACHE; HEALTH CARE POLICY; HEART ARRHYTHMIA; HEART FAILURE; HEART INFARCTION; HEARTBURN; HEMOLYSIS; HEPATITIS; HIP FRACTURE; HUMAN; HYPERBILIRUBINEMIA; HYPERCALCEMIA; HYPERCALCIURIA; HYPERGLYCEMIA; HYPERPIGMENTATION; HYPERURICEMIA; HYPERVITAMINOSIS; INFLAMMATION; INFORMATION RETRIEVAL; INJECTION SITE REACTION; INJECTION SITE SWELLING; INSOMNIA; INTRACRANIAL PRESSURE; IRRITABILITY; JAUNDICE; LETHARGY; LIPID BLOOD LEVEL; LIVER INJURY; LIVER TOXICITY; LUNG CANCER; LUNG EDEMA; MALAISE; MASTALGIA; MAXIMUM TOLERATED DOSE; METASTATIC CALCIFICATION; MUSCLE HYPOTONIA; MYALGIA; NAUSEA; NEPHROLITHIASIS; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; OSTEOSCLEROSIS; PAIN; PANCREATITIS; PAPULE; PEPTIC ULCER; PERICARDIAL EFFUSION; PHOTOPHOBIA; PHOTOSENSITIVITY; POLYURIA; POSTMENOPAUSE; PRENATAL EXPOSURE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; PROTHROMBIN TIME; PRURITUS; PSYCHOSIS; PUSTULE; RANDOMIZED CONTROLLED TRIAL; RASH; RESPIRATORY DISTRESS; RESTLESSNESS; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; ROSACEA; ROSACEA FULMINANS; SEIZURE; SENSORY ATAXIA; SENSORY NEUROPATHY; SIDE EFFECT; SKIN IRRITATION; SKIN NODULE; SKIN TINGLING; SLEEP DISORDER; SMOKING; SOMNOLENCE; STOMACH CARCINOMA; STROKE; SWEATING; SYNCOPE; TACHYCARDIA; THIRST; THROMBOCYTE AGGREGATION; THROMBOPHLEBITIS; THROMBOSIS; THYROID DISEASE; TOXIC AMBLYOPIA; TREATMENT CONTRAINDICATION; ULCERATIVE COLITIS; UREA NITROGEN BLOOD LEVEL; UREMIA; URINARY EXCRETION; URINARY FREQUENCY; URINE COLOR; URTICARIA; VERTIGO; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; VOMITING; WEAKNESS; WEIGHT REDUCTION;

ANIMALS; CANADA; CHILD; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; DRUG LABELING; HUMANS; NONPRESCRIPTION DRUGS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOLUBILITY; UNITED STATES; VITAMINS;

EID: 76149109755     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M238     Document Type: Review

References (147)

1. Radimer K, Bindewald B, Hughes J, et al. Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidemiol 2004;160:339- 49. DOI 10.1093/aje/kwh207
2. What is CAM? The National Center for Complementary and Alternative Medicine (NCCAM). The National Institutes of Health. http://nccam.nih.gov/ health/whatiscam/ (accessed 2009 Oct 15).
3. Dietary Supplement Health and Education Act of 1994. Public Law 103-417. 103rd Congress. www.fda.gov/opacom/Laws/dshea.html (accessed 2009 Oct 15).
4. Gulati OP, Berry Ottaway P. Legislation relating to nutraceuticals in the European Union with a particular focus on botanical-sourced products. Toxicology 2006;221:75-87. DOI 10.1016/j.tox.2006.01.014
5. Her Majesty the Queen. Natural health product regulations. Canada Gazette Part II 2003;137:1562-607. http://gazette.gc.ca/archives/p2/2003/2003-06-18/ html/sor-dors196-eng.html.
6. Timbo BB, Ross MP, McCarthy PV, et al. Dietary supplements in a national survey: prevalence of use and reports of adverse events. J Am Diet Assoc 2006;106:1966-74. DOI 10.1016/j.jada.2006.09.002
7. NIH State-of-the-Science Panel. National Institutes of Health State-of-the-science conference statement: multivitamin/mineral supplements and chronic disease prevention. Ann Intern Med 2006;145:364-71.
8. Lee Y, Mitchell DC, Smiciklas-Wright H, et al. Maternal influences on 5- to 7-year-old girls' intake of multivitamin-mineral supplements. Pediatrics 2002;109:E46. DOI 10.1542/peds.109.3.e46
9. Department of Health and Human Services. Food and Drug Administration. 21 CFR PART 345. Vitamin and mineral drug products for over-the-counter human use; withdrawal of proposed monograph. www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/ DevelopmentResources/Over-the-CounterOTCDrugs/ StatusofOTCRulemakings/ ucm089181.pdf. Fed Reg 1981;46:57914-5.
10. Drugs, Supplements, and Herbal Information. MedlinePlus, a service of the US National Library of Medicine and the National Institutes of Health. www.nlm.nih.gov/medlineplus/druginformation.html (accessed 2009 Oct 15).
11. Check interactions. Drug Digest. www.drugdigest.org/DD/Interaction/ ChooseDrugs (accessed 2009 Oct 15).
12. Natural Medicine Comprehensive Database. www.naturaldatabase.com (accessed 2009 Oct 15).
13. Interactions by herb or supplement. Medical references, University of Maryland Medical Center. www.umm.edu/altmed/ConsLookups/InteractionsByHerbSupp. html (accessed 2009 Oct 15).
14. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 1998;280:1569-75. DOI 10.1001/jama.280.18.1569
15. Troppmann L, Johns T, Gray-Donald K. Natural health product use in Canada. Can J Public Health 2002;93:426-30.
16. Crawford NW, Cincotta DR, Lim A, et al. A cross-sectional survey of complementary and alternative medicine use by children and adolescents attending the University Hospital of Wales. BMC Complement Altern Med 2006;6:16.e1-16.e10.
17. Singh SR, Levine MA. Natural health product use in Canada: analysis of the National Population Health Survey. Can J Clin Pharmacol 2006;13: e240-50.
18. Singh SR, Levine MA. Potential interactions between pharmaceuticals and natural health products in Canada. J Clin Pharmacol 2007;47:249-58. DOI 10.1177/009127000629642
19. Braun CA, Bearinger LH, Halcon LL, et al. Adolescent use of complementary therapies. J Adolesc Health 2005;37:76.e1-76.e9. DOI 10.1016/j.jadohealth.2004. 07.010
20. Dwyer JT, Garcea AO, Evans M, et al. Do adolescent vitamin-mineral supplement users have better nutrient intakes than nonusers? Observations from the CATCH tracking study. J Am Diet Assoc 2001;101:1340-6. DOI 10.1016/S0002-8223(01)00321-2
21. Goldman RD, Rogovik AL, Lai D, et al. Potential interactions of drugnatural health products and natural health products-natural health products among children. J Pediatr 2008;152:521-6. DOI 10.1016/j.jpeds.2007.09.026
22. Sichert-Hellert W, Kersting M. Vitamin and mineral supplements use in German children and adolescents between 1986 and 2003: results of the DONALD Study. Ann Nutr Metab 2004;48:414-9. DOI 10.1159/000083574
23. Yu SM, Kogan MD, Gergen P. Vitamin-mineral supplement use among preschool children in the United States. Pediatrics 1997;100:E4. DOI 10.1542/peds.100.5. e4
24. Briefel R, Hanson C, Fox MK, et al. Feeding Infants and Toddlers Study: do vitamin and mineral supplements contribute to nutrient adequacy or excess among US infants and toddlers? J Am Diet Assoc 2006;106:S52-65. DOI 10.1016/j.jada.2005.09.041
25. Woo JJ. Adverse event monitoring and multivitamin-multimineral dietary supplements. Am J Clin Nutr 2007;85:323S-4S.
26. Mulholland CA, Benford DJ. What is known about the safety of multivitamin-multimineral supplements for the generally healthy population? Theoretical basis for harm. Am J Clin Nutr 2007;85:318S-22S.
27. Russell RM. The vitamin A spectrum: from deficiency to toxicity. Am J Clin Nutr 2000;71:878-84.
28. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganese, molybdenum, nickel, silicon, vanadium, and zinc. Washington, DC: National Academy Press, 2002. www.nap.edu/catalog.php?record-id=10026.
29. McKevoy GK, ed. AHFS drug information. Bethesda, MD: American Society of Health-System Pharmacists, 1998.
30. Rothman KJ, Moore LL, Singer MR, et al. Teratogenicity of high vitamin A intake. N Engl J Med 1995;333:1369-73. DOI 10.1056/NEJM199511233332101
31. Feskanich D, Singh V, Willett WC, et al. Vitamin A intake and hip fractures among postmenopausal women. JAMA 2002;287:47-54. DOI 10.1001/jama.287.1.47
32. Michaelsson K, Lithell H, Vessby B, Melhus H. Serum retinol levels and the risk of fracture. N Engl J Med 2003;348:287-94. DOI 10.1056/NEJMoa021171
33. Melhus H, Michaelsson K, Kindmark A, et al. Excessive dietary intake of vitamin A is associated with reduced bone mineral density and increased risk for hip fracture. Ann Intern Med 1998;129:770-8.
34. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35. DOI 10.1056/ NEJM199404143301501
35. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-5. DOI 10.1056/NEJM199605023341802
36. Lee IM, Cook NR, Manson JE, et al. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women's Health Study. J Natl Cancer Inst 1999;91:2102-6. DOI 10.1093/jnci/91.24.2102
37. Goodman GE, Thornquist MD, Balmes J, et al. The Beta-Carotene and Retinol Efficacy Trial: incidence of lung cancer and cardiovascular disease mortality during 6-year follow-up after stopping beta-carotene and retinol supplements. J Natl Cancer Inst 2004;96:1743-50. DOI 10.1093/jnci/djh320
38. Botterweck AA, van den Brandt PA, Goldbohm RA. Vitamins, carotenoids, dietary fiber, and the risk of gastric carcinoma: results from a prospective study after 6.3 years of follow-up. Cancer 2000;88:737- 48. DOI 10.1002/(SICI)1097-0142(20000215)88:4<737::AID -CNCR2>3.3. CO;2-8
39. Fawzi WW, Mbise R, Spiegelman D, Fataki M, Hertzmark E, Ndossi G. Vitamin A supplements and diarrheal and respiratory tract infections among children in Dar es Salaam, Tanzania. J Pediatr 2000;137:660-7. DOI 10.1067/mpd.2000.110136
40. Bendich A, Machlin LJ. Safety of oral intake of vitamin E. Am J Clin Nutr 1988;48:612-9.
41. Fairfield KM, Fletcher RH. Vitamins for chronic disease prevention in adults: scientific review. JAMA 2002;287:3116-26. DOI 10.1001/jama.287.23.3116
42. Seifried HE, McDonald SS, Anderson DE, et al. The antioxidant conundrum in cancer. Cancer Res 2003;63:4295-8.
43. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Soprawivenza nell'Infarto miocardico. Lancet 1999;354:447-55. DOI 10.1016/S0140-6736(99)07072-5
44. Marchioli R, Levantesi G, Macchia A, et al; GISSI-Prevenzione Investigators. Vitamin E increases the risk of developing heart failure after myocardial infarction: results from the GISSI-Prevenzione trial. J Cardiovasc Med (Hagerstown) 2006;7:347-50.
45. Yusuf S, Dagenais G, Pogue J, et al. Vitamin E supplementation and cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 2000;342:154-60. DOI 10.1056/NEJM200001203420302
46. Lonn E, Bosch J, Yusuf S, et al. HOPE and HOPE-TOO trial investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 2005;293:1338-47. DOI 10.1001/jama.293.11.1338
47. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for vitamin C, vitamin E, selenium, and carotenoids. Washington, DC: National Academy Press, 2000. www.nap.edu/catalog.php?record-id=9810.
48. Booth SL, Golly I, Sacheck JM, et al. Effect of vitamin E supplementation on vitamin K status in adults with normal coagulation status. Am J Clin Nutr 2004;80:143-8.
49. Miller ER 3rd, Pastor-Barriuso R, Dalal D, et al. Meta-analysis: highdosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 2005;142:60520-53. DOI 10.1016/j.accreview.2005.04.017
50. Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297:842-57. DOI 10.1001/jama.297.8.842
51. Hayden KM, Welsh-Bohmer KA, Wengreen HJ, et al; Cache County investigators. Risk of mortality with vitamin E supplements: the Cache County study. Am J Med 2007;120:180- 4. DOI 10.1016/j.amjmed.2006.03.039
52. Kabat GC, Kim M, Adams-Campbell LL, et al; WHI investigators. Longitudinal study of serum carotenoid, retinol, and tocopherol concentrations in relation to breast cancer risk among postmenopausal women. Am J Clin Nutr 2009;90:162-9. DOI 10.3945/ajcn.2009.27568
53. Meyer F, Galan P, Douville P, et al. Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer 2005;116:182-6. DOI 10.1002/ijc.21058
54. Lawson KA, Wright ME, Subar A, et al. Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health study. J Natl Cancer Inst 2007;99:754-64. DOI 10.1093/jnci/djk177
55. Brodkin RH, Bleiberg J. Sensitivity to topically applied vitamin E. Arch Dermatol 1965;92:76-7. DOI 10.1001/archderm.92.1.76
56. Koutkia P, Chen TC, Holick MF. Vitamin D intoxication associated with an over-the-counter supplement. N Engl J Med 2001;345:66-7. DOI 10.1056/NEJM200107053450115
57. Klontz KC, Acheson DW. Dietary supplement-induced vitamin D intoxication. N Engl J Med 2007;357:308-9. DOI 10.1056/NEJMc063341
58. Barrueto F Jr, Wang-Flores HH, Howland MA, Hoffman RS, Nelson LS. Acute vitamin D intoxication in a child. Pediatrics 2005;116:e453-6. DOI 10.1542/peds.2004-2580
59. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and fluoride. Washington, DC: National Academy Press, 1999. www.nap.edu/openbook.php?isbn = 0309063507.
60. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-83. DOI 10.1056/NEJMoa055218
61. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline. Washington, DC: National Academy Press, 2000. www.nap.edu/catalog.php?record-id = 6015.
62. Eichholzer M, Lüthy J, Moser U, Stähelin HB, Gutzwiller F. Safety aspects of folic acid for the general population. Praxis (Bern 1994) 2002;91:7-16.
63. Morris MC, Evans DA, Bienias JL, et al. Dietary folate and vitamin B12 intake and cognitive decline among community-dwelling older persons. Arch Neurol 2005;62:641-5. DOI 10.1001/archneur.62.4.641
64. Lange H, Suryapranata H, De Luca G, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004;350:2673-81. DOI 10.1056/NEJMoa032845
65. Bonaa KH, Njolstad I, Ueland PM, et al. NORVIT: homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 2006;354:1578-88. DOI 10.1056/NEJMoa055227
66. Figueiredo JC, Grau MV, Haile RW, et al. Folic acid and risk of prostate cancer: results from a randomized clinical trial. J Natl Cancer Inst 2009;101:432-5. DOI 10.1093/jnci/djp019
67. Charles D, Ness AR, Campbell D, et al. Taking folate in pregnancy and risk of maternal breast cancer. Br Med J 2004;329:1375-6. DOI 10.1136/bmj.329.7479.1375
68. Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987;2:10-32.
69. Figge HL, Figge J, Souney PF, et al. Nicotinic acid: a review of its clinical use in the treatment of lipid disorders. Pharmacotherapy 1988;8:287-94.
70. ASHP therapeutic position statement on the safe use of niacin in the management of dyslipidemias. Am J Health Syst Pharm 1997;54:2815-9.
71. Rader JI, Calvert RJ, Hathcock JN. Hepatic toxicity of unmodified and time-release preparations of niacin. Am J Med 1992;92:77-81. DOI 10.1016/0002-9343(92)90018-7
72. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 2004;164:697-705. DOI 10.1001/archinte.164.7. 697
73. Hoskin PJ, Stratford MR, Saunders MI, et al. Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity. Int J Radiat Oncol Biol Phys 1995;32:1111-9. DOI 10.1016/0360-3016(95) 00022-Q
74. Kahn SE, Beard JC, Schwartz MW, et al. Increased B-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989;38:562-8. DOI 10.2337/diabetes.38.5.562
75. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes mellitus. JAMA 1990;264:723-6. DOI 10.1001/jama.264.6.723
76. Pozzilli P, Browne PD, Kolb H. Meta-analysis of nicotinamide treatment in patients with recent-onset IDDM. The Nicotinamide Trialists. Diabetes Care 1996;19:1357-63. DOI 10.2337/diacare.19.12.1357
77. Garg R, Malinow MR, Pettinger M, et al. Niacin treatment increases plasma homocysteine levels. Am Heart J 1999;138:1082-7.
78. Miralbell R, Mornex F, Greiner R, et al. Accelerated radiotherapy, carbogen, and nicotinamide in glioblastoma multiforme: report of European Organization for Research and Treatment of Cancer trial 22933. J Clin Oncol 1999;17:3143-9.
79. Levine M, Rumsey SC, Daruwala R, et al. Criteria and recommendations for vitamin C intake. JAMA 1999;281:1415-23. DOI 10.1001/jama.281.15.1415
80. Traxer O, Huet B, Poindexter J, et al. Effect of ascorbic acid consumption on urinary stone risk factors. J Urol 2003;170:397- 401. DOI 10.1097/01.ju.0000076001.21606.53
81. Taylor EN, Stampfer MJ, Curhan GC. Dietary factors and the risk of incident kidney stones in men: new insights after 14 years of follow-up. J Am Soc Nephrol 2004;15:3225-32. DOI 10.1097/01.ASN.0000146012.44570.20
82. Dwyer JH, Paul-Labrador MJ, Fan J, Shircore AM, Merz CN, Dwyer KM. Progression of carotid intima-media thickness and plasma antioxidants: the Los Angeles Atherosclerosis study. Arterioscler Thromb Vasc Biol 2004;24:313-9. DOI 10.1161/01.ATV.0000109955.80818.8a
83. Lee DH, Folsom AR, Harnack L, et al. Does supplemental vitamin C increase cardiovascular disease risk in women with diabetes? Am J Clin Nutr 2004;80:1194-200.
84. Lee SH, Oe T, Blair IA. Vitamin C - induced decomposition of lipid hydroperoxides to endogenous genotoxins. Science 2001;292:2083- 4. DOI 10.1126/science.1059501
85. Bendich A, Cohen M. Vitamin B6 safety issues. Ann N Y Acad Sci 1990;585:321-30. DOI 10.1111/j.1749-6632.1990.tb28064.x
86. Geerling BJ, Dagnelie PC, Badart-Smook A, et al. Diet as a risk factor for the development of ulcerative colitis. Am J Gastroenterol 2000; 95:1008-13. DOI 10.1111/j.1572-0241.2000.01942.x
87. Vasile A, Goldberg R, Kornberg B. Pyridoxine toxicity: report of a case. J Am Osteopath Assoc 1984;83:790-1.
88. Jansen T, Romiti R, Kreuter A, Altmeyer P. Rosacea fulminans triggered by high-dose vitamins B6 and B12. J Eur Acad Dermatol Venereol 2001;15:484-5. DOI 10.1046/j.1468-3083.2001.00308.x
89. Kawada A, Kashima A, Shiraishi H, et al. Pyridoxine-induced photosensitivity and hypophosphatasia. Dermatology 2000;201:356-60. DOI 10.1159/000051555
90. 5 and H. Ann Pharmacother 2001;35:424-6. DOI 10.1345/aph.10213
91. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998;50:466-70.
92. Day E, Bentham P, Callaghan R, et al. Thiamine for Wernicke-Korsakoff syndrome in people at risk from alcohol abuse. Cochrane Database Syst Rev 2004;(1):CD004033. DOI 10.1002/14651858.CD004033.pub2
93. Stucker M, Memmel U, Hoffmann M, et al. Vitamin B(12) cream containing avocado oil in the therapy of plaque psoriasis. Dermatology 2001;203:141-7. DOI 10.1159/000051729
94. Yetley EA. Multivitamin and multimineral dietary supplements: definitions, characterization, bioavailability, and drug interactions. Am J Clin Nutr 2007;85:269S-76S.
95. Goldman RD, Vohra S, Rogovik AL. Potential vitamin-drug interactions in children: at a pediatric emergency department. Paediatr Drugs 2009; 11:251-7.
96. Maskos Z, Koppenol WH. Oxyradicals and multivitamin tablets. Free Radic Biol Med 1991;11:609-10. DOI 10.1016/0891-5849(91)90142-P
97. Goldsmith LA, Bolognia JL, Callen JP, et al; American Academy of Dermatology. American Academy of Dermatology Consensus Conference on the safe and optimal use of isotretinoin: summary and recommendations. J Am Acad Dermatol 2004;50:900-6. DOI 10.1016/j.jaad.2004.02.012
98. Hansten PD, Horn JR. Drug interactions analysis and management. Vancouver, WA: Applied Therapeutics Inc., 2008. www.hanstenandhorn.com/book- DIAM.htm.
99. Hathcock JN, Hattan DG, Jenkins MY, et al. Evaluation of vitamin A toxicity. Am J Clin Nutr 1990;52:183-202.
100. Walters BN, Gubbay SS. Tetracycline and benign intracranial hypertension: report of five cases. Br Med J 1981;282:19-20. DOI 10.1136/bmj.282.6257.19
101. Liede KE, Haukka JK, Saxen LM, et al. Increased tendency towards gingival bleeding caused by joint effect of alpha-tocopherol supplementation and acetylsalicylic acid. Ann Med 1998;30:542-6. DOI 10.3109/07853899809002602
102. Corrigan JJ Jr. The effect of vitamin E on warfarin-induced vitamin K deficiency. Ann N Y Acad Sci 1982;393:361-8. DOI 10.1111/j.1749-6632.1982. tb31275.x
103. Moon J. The role of vitamin D in toxic metal absorption: a review. J Am Coll Nutr 1994;13:559-64.
104. Adler AJ, Berlyne GM. Duodenal aluminum absorption in the rat: effect of vitamin D. Am J Physiol 1985;249:G209-13.
105. Demontis R, Leflon A, Fournier A, et al. 1 alpha(OH) Vitamin D3 increases plasma aluminum in hemodialyzed patients taking AI(OH)3. Clin Nephrol 1986;26:146-9.
106. Demontis R, Reissi D, Noel C, et al. Indirect clinical evidence that 1 alpha OH vitamin D3 increases the intestinal absorption of aluminum. Clin Nephrol 1989;31:123-7.
107. Tatro DS, ed. Drug interaction facts. St. Louis, MO: Facts and Comparisons Inc., 2008.
108. Thiazide diuretics and the risk of osteoporosis. Pharmacist's Letter/Prescriber's Letter 2003;19:191105.
109. Crowe M, Wollner L, Griffiths RA. Hypercalcemia following vitamin D and thiazide therapy in the elderly. Practitioner 1984;228:312-3.
110. Parfitt AM. Thiazide-induced hypercalcemia in vitamin D - treated hypoparathyroidism. Ann Intern Med 1972;77:557-63.
111. Bar-Or D, Gasiel Y. Calcium and calciferol antagonize effect of verapamil in atrial fibrillation. Br Med J 1981;282:1585-6. DOI 10.1136/bmj.282.6276. 1585-a
112. Baggott JE, Morgan SL, Ha T, et al. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J 1992;282:197-202.
113. Schroder H, Clausen N, Ostergard E, Pressler T. Folic acid supplements in vitamin tablets: a determinant of hematological drug tolerance in maintenance therapy of childhood acute lymphoblastic leukemia. Ped Hematol Oncol 1986;3:241-7. DOI 10.3109/08880018609031223
114. Dijkmans BA. Folate supplementation and methotrexate. Br J Rheumatol 1995;34:1172-4. DOI 10.1093/rheumatology/34.12.1172
115. Ortiz Z, Shea B, Suarez Almazor M, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (Cochrane Review). Cochrane Database Syst Rev 2000;2: CD000951. DOI 10.1002/14651858.CD000951
116. Froscher W, Maier V, Laage M, et al. Folate deficiency, anticonvulsant drugs, and psychiatric morbidity. Clin Neuropharmacol 1995;18:165-82. DOI 10.1097/00002826-199504000-00008
117. Lewis DP, Van Dyke DC, Willhite LA, et al. Phenytoin-folic acid interaction. Ann Pharmacother 1995;29:726-35.
118. Lambie DG, Johnson RH. Drugs and folate metabolism. Drugs 1985;30:145-55. DOI 10.2165/00003495-198530020-00003
119. Van Delden C, Hirschel B. Folinic acid supplements to pyrimethamine-sulfadiazine for Toxoplasma encephalitis are associated with better outcome (letter). J Infect Dis 1996;173:1294-5.
120. Schwartz ML. Severe reversible hyperglycemia as a consequence of niacin therapy. Arch Int Med 1993;153:2050-2. DOI 10.1001/archinte.153.17.2050
121. Ding RW, Kolbe K, Merz B, et al. Pharmacokinetics of nicotinic acid - salicylic acid interaction. Clin Pharmacol Ther 1989;46:642-7. 122. Bays HE, Dujovne CA. Drug interactions of lipid-altering drugs. Drug Saf 1998;19:355-71. DOI 10.2165/00002018-199819050-00003
122. Bourgeois BF, Dodson WE, Ferrendelli JA. Interactions between primidone, carbamazepine, and nicotinamide. Neurology 1982;32:1122-6..
123. Reaven P, Witztum JL. Lovastatin, nicotinic acid and rhabdomyolysis (letter). Ann Int Med 1988;109:597-8.
124. Houston JB, Levy G. Drug biotransformation interactions in man VI: acetaminophen and ascorbic acid. J Pharm Sci 1976;65:1218-21. DOI 10.1002/jps.2600650822
125. Buttery JE, Boord S, Ludvigsen H. Ascorbate interference in the urinary screen for acetaminophen. Clin Chem 1988;34:769.
126. Domingo JL, Gomez M, Llobet JM, et al. Effect of ascorbic acid on gastrointestinal aluminium absorption. Lancet 1991;338:1467. DOI 10.1016/0140-6736(91)92776-X
127. Konturek PC, Kania J, Hahn EG, et al. Ascorbic acid attenuates aspirin-induced gastric damage: role of inducible nitric oxide synthase. J Physiol Pharmacol 2006;57:125-36.
128. Gonzalez JP, Valdivieso A, Calvo R, et al. Influence of vitamin C on the absorption and first pass metabolism of propranolol. Eur J Clin Pharmacol 1995;48:295-7. DOI 10.1007/BF00198315
129. Labriola D, Livingston R. Possible interactions between dietary antioxidants and chemotherapy. Oncology 1999;13:1003-8. www.ncbi.nlm.nih.gov/ pubmed/10442346.
130. Heaney ML, Gardner JR, Karasavvas N, et al. Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res 2008;68:8031-8. DOI 10.1158/0008-5472.CAN-08-1490
131. Back DJ, Breckenridge AM, MacIver M, et al. Interaction of ethinyloestradiol with ascorbic acid in man. Br Med J (Clin Res Ed) 1981;282:1516. DOI 10.1136/bmj.282.6275.1516
132. Vihtamaki T, Parantainen J, Koivisto AM, et al. Oral ascorbic acid increases plasma oestradiol during postmenopausal hormone replacement therapy. Maturitas 2002;42:129-35. DOI 10.1016/S0378-5122(02)00005-1
133. Dysken MW, Cumming RJ, Channon RA, Davis JM. Drug interaction between ascorbic acid and fluphenazine. JAMA 1979;241:2008. DOI 10.1001/jama.241.19. 2008b
134. Slain D, Amsden JR, Khakoo RA, et al. Effect of high-dose vitamin C on the steady-state pharmacokinetics of the protease inhibitor indinavir in healthy volunteers. Pharmacotherapy 2005;25:165-70. DOI 10.1592/phco.25.2.165.56945
135. Mallory MA, Sthapanachai C, Kowdley KV. Iron overload related to excessive vitamin C intake (letter). Ann Intern Med 2003;139:532-3.
136. Feetam CL, Leach RH, Meynell MJ. Lack of a clinically important interaction between warfarin and ascorbic acid. Toxicol Appl Pharmacol 1975;31:544-7. DOI 10.1016/0041-008X(75)90278-1
137. Rosenthal G. Interaction of ascorbic acid and warfarin. JAMA 1971;215:1671. DOI 10.1001/jama.215.10.1671b
138. Smith EC, Skalski RJ, Johnson GC, Rossi GV. Interaction of ascorbic acid and warfarin. JAMA 1972;221:1166. DOI 10.1001/jama.221.10.1166b
139. Hume R, Johnstone JM, Weyers E. Interaction of ascorbic acid and warfarin. JAMA 1972;219:1479. DOI 10.1001/jama.219.11.1479b
140. Weintraub M, Griner PF. Warfarin and ascorbic acid: lack of evidence for a drug interaction. Toxicol Appl Pharmacol 1974;28:53-6. DOI 10.1016/0041-008X(74)90130-6
141. Hansson O, Sillanpaa M. Letter: pyridoxine and serum concentration of phenytoin and phenobarbitone. Lancet 1976;1:256. DOI 10.1016/S0140-6736(76) 91385-4
142. Falguera M, Perez-Mur J, Puig T, et al. Study of the role of vitamin B12 and folinic acid supplementation in preventing hematologic toxicity of zidovudine. Eur J Haematol 1995;55:97-102.
143. Food and Drug Administration. Regulatory mechanisms for marketing OTC drug products. www.fda.gov/AboutFDA/CentersOffices/CDER/ucm106386.htm#monograph (accessed 2009 Oct 15).
144. Food and Drugs Act. http://Laws.justice.gc.ca/PDF/Statute/F/F-27. pdf(accessed 2009 Oct 15).
145. Food and Drug Regulations. http://Laws.justice.gc.ca/PDF/Regulation/C/C. R.C.,-c.-870.pdf. (accessed 2009 Oct 15).
146. Food and Nutrition Board, Institute of Medicine. Dietary reference intakes: guiding principles for nutrition labeling and fortification. Washington, DC: National Academy Press, 2003. www.nap.edu/catalog.php?record-id = 10872.
147. Beauchesne E, Kondro W. Health Canada contemplates providing food industry with "discretionary" authority to fortify junk foods. CMAJ 2009;180:1196-7. DOI 10.1503/cmaj.090897